Prognostic factors in aggressive non-Hodgkin's lymphomas

Oncologist

Volumn 3, Issue 3, 1998, Pages 189-197

  Nicolaides, Costas ^a   Dimou, Sofia ^a   Pavlidis, Nicholas ^a,b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Non Hodgkin's lymphoma; Prognostic factors

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GLYCOPROTEIN P; HEMOGLOBIN; METHOTREXATE; PREDNISONE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; ERYTHROCYTE SEDIMENTATION RATE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 0031782386     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.3-3-189     Document Type: Article

References (15)

1. Hairis NL, Jaffe ES, Stein ES et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392.
2. Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-2135.
3. Coltman CA, Dahlberg S, Jones SE et al. CHOP is curative in thirty percent of patients with diffuse large cell lymphoma: a twelve year Southwest Oncology Group follow up. Proc Am Soc Clin Oncol 1986;5:197.
4. Skarin AT, Canellos GP, Rosenthal DS et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1983;2:91-98.
5. Shipp MA, Yeap BY, Harrington DP et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with M-BACOD regimen. J Clin Oncol 1990;8:84-93.
6. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 1985;102:596-602.
7. Longo DL, DeVita VT Jr, Duffey PL et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized tria!. J Clin Oncol 1991;9:25-38.
8. Boyd DB, Coleman M, Parish SW et al. COPBLAM III: Infusional combination chemotherapy for diffuse large-cell lymphoma. J Clin Oncol 1988;6:425-433.
9. Coiffier B, Gisselbrecht C, Herbrecht R et al. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989;7:1018-1026.
10. Gordon LI, Harrington D, Andersen J et al. Comparison of a second generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992;327:1342-1349.
11. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
12. Cabanillas F, Velasquez WS, Hagemeister FB et al. Clinical biologic and histologic features of late relapses in diffuse large cell lymphoma. Blood 1992;79:1024-1028.
13. Shipp MA, Harrington DP, Klatt MM et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986;104:757-765.
14. Jaganath S, Velasquez WS, Tucker SL et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol 1986;4:859-865.
15. Velasquez WS, Jagannath S, Tucker SL et al. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived for 10 year survival data. Blood 1989;74:551-557.